ICAAC Briefs: BioCryst Flu Candidate Rapivab, Melinta’s Delafloxacin For Gonorrhea And More
The Interscience Conference on Antimicrobial Agents and Chemotherapy included presentations on Phase I study of delafloxacin for uncomplicated gonorrhea, Biocryst’s placebo-controlled flu trials of Rapivab and in vitro studies of Theravance’s Vibativ versus vancomycin.
You may also be interested in...
Synthetic Biologics thinks it can produce first product to prevent C. difficile infections by protecting microbiome from impact of I.V. beta lactam antibiotics; biotech plans IND in next two months and hopes to produce proof-of-concept data within roughly one year.
The market for diagnostic and infection control products will see continued growth as hospitals and other providers look to the technology sector to help fight the battle against health care-associated infections and antibiotic-resistant organisms.
The biotech is bringing is long-plagued antibiotic back to U.S. patients, but is still searching for another company to help with commercialization efforts. Meanwhile, plans for its split and the launch of its partnered COPD drug are on track.